| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Michael A. Carducci | Q114718060 |
| Emmanuel S. Antonarakis | Q79135452 | ||
| P2093 | author name string | Mario A Eisenberger | |
| P2860 | cites work | Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors | Q83390295 |
| Development of a second-generation antiandrogen for treatment of advanced prostate cancer | Q24605577 | ||
| Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer | Q24632187 | ||
| Targeting the mTOR signaling network for cancer therapy | Q24658334 | ||
| Estimating the precursor frequency of naive antigen-specific CD8 T cells | Q24674109 | ||
| A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer | Q25255692 | ||
| Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. | Q27824772 | ||
| Cancer statistics, 2008 | Q27860585 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| The endothelin axis: emerging role in cancer | Q28206793 | ||
| Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis | Q28258638 | ||
| Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion | Q28281101 | ||
| Sorafenib in advanced clear-cell renal-cell carcinoma | Q28282767 | ||
| Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model | Q28296122 | ||
| Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides | Q28377931 | ||
| The phosphatidylinositol 3-Kinase AKT pathway in human cancer | Q29547860 | ||
| The TOR pathway: a target for cancer therapy | Q29614242 | ||
| Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer | Q29616218 | ||
| Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial | Q29618031 | ||
| Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models | Q46157345 | ||
| Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer | Q46252104 | ||
| A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer | Q46336471 | ||
| Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer | Q46341615 | ||
| A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer | Q46493707 | ||
| Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study | Q46752908 | ||
| Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study | Q46817220 | ||
| A phase II clinical trial of sorafenib in androgen-independent prostate cancer | Q46825505 | ||
| Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases | Q46972241 | ||
| A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer | Q48456368 | ||
| Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. | Q51803777 | ||
| The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. | Q53890793 | ||
| Thalidomide | Q56091164 | ||
| Racial Disparity of Epidermal Growth Factor Receptor Expression in Prostate Cancer | Q57908276 | ||
| Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer | Q60156367 | ||
| Epigenetic regulation of androgen receptor gene expression in human prostate cancers | Q73351299 | ||
| Expression of endothelin receptor a associated with prostate cancer progression | Q73436802 | ||
| Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer | Q74293224 | ||
| Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 | Q74597471 | ||
| Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators | Q79794482 | ||
| Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer | Q80352321 | ||
| Increased metastatic lymph node 64 and CYP17 expression are associated with high stage prostate cancer | Q80528146 | ||
| Drug evaluation: CP-751871, a human antibody against type I insulin-like growth factor receptor for the potential treatment of cancer | Q80560556 | ||
| Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 tria | Q82766552 | ||
| Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma | Q29618608 | ||
| Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate | Q33184380 | ||
| Autoantibody signatures in prostate cancer | Q33223730 | ||
| Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer | Q33360724 | ||
| Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma | Q33375600 | ||
| Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. | Q33383770 | ||
| Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group | Q33566395 | ||
| Natural history of progression after PSA elevation following radical prostatectomy | Q33611613 | ||
| Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. | Q33638830 | ||
| CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy | Q33937501 | ||
| An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice | Q33943166 | ||
| An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer | Q34066960 | ||
| Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. | Q34128471 | ||
| The rapamycin-sensitive signal transduction pathway as a target for cancer therapy | Q34293622 | ||
| Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity | Q34334817 | ||
| Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer | Q34543188 | ||
| Emerging targets in the AKT pathway for treatment of androgen-independent prostatic adenocarcinoma | Q34568941 | ||
| Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer | Q34578443 | ||
| CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer | Q34604646 | ||
| Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters | Q34605766 | ||
| Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. | Q34772133 | ||
| Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. | Q34798892 | ||
| Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer | Q34898980 | ||
| GM-CSF-secreting melanoma vaccines | Q35146599 | ||
| New strategies for active immunotherapy with genetically engineered tumor cells | Q35454126 | ||
| Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer | Q35559975 | ||
| DNA methylation changes in prostate cancer: current developments and future clinical implementation | Q35636543 | ||
| Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance | Q35690984 | ||
| Clinical development of anti-RANKL therapy | Q35901092 | ||
| Atrasentan: targeting the endothelin axis in prostate cancer | Q35964727 | ||
| A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases | Q35978728 | ||
| The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). | Q36114755 | ||
| Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. | Q36163574 | ||
| Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer | Q36254081 | ||
| In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration | Q36259619 | ||
| Prostate cancer immunology: biology, therapeutics, and challenges | Q36309729 | ||
| Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale | Q36469810 | ||
| Targeting bone metastasis in prostate cancer with endothelin receptor antagonists | Q36633818 | ||
| Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. | Q36780750 | ||
| IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor | Q36944397 | ||
| Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study | Q36999978 | ||
| GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer | Q37012084 | ||
| Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer | Q37038179 | ||
| The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer | Q37038979 | ||
| RANKL inhibition in the treatment of bone metastases | Q37237187 | ||
| Implications of insulin-like growth factor-I for prostate cancer therapies | Q37381766 | ||
| Immunotherapeutics in development for prostate cancer | Q37431076 | ||
| Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. | Q38467346 | ||
| Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics | Q39408230 | ||
| Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer | Q39958481 | ||
| Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa | Q39958561 | ||
| bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer | Q40027572 | ||
| An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer | Q40058982 | ||
| In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer | Q40144512 | ||
| In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors | Q40433669 | ||
| Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. | Q40448896 | ||
| The inhibitory effects of gossypol on human prostate cancer cells-PC3 are associated with transforming growth factor beta1 (TGFbeta1) signal transduction pathway. | Q40579727 | ||
| AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression | Q40623520 | ||
| Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. | Q40692658 | ||
| Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo | Q41288594 | ||
| Osteoprotegerin and rank ligand expression in prostate cancer | Q42502915 | ||
| A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. | Q42654377 | ||
| Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. | Q43670874 | ||
| Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer | Q44265664 | ||
| Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial | Q44315403 | ||
| Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma | Q44551425 | ||
| Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. | Q44615027 | ||
| Combination chemotherapy for hormone-refractory prostate carcinoma: progress and pitfalls | Q44644568 | ||
| Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). | Q44799712 | ||
| The evolution of thalidomide and its IMiD derivatives as anticancer agents | Q44824886 | ||
| Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer | Q44889720 | ||
| Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer | Q44958682 | ||
| Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer | Q45018087 | ||
| Mechanisms of androgen-refractory prostate cancer | Q45094999 | ||
| Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group | Q45230542 | ||
| Demonstration of a rational strategy for human prostate cancer gene therapy | Q45873845 | ||
| Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. | Q46023216 | ||
| Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines | Q46134829 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| prostate neoplasm | Q56014511 | ||
| P304 | page(s) | 1-13 | |
| P577 | publication date | 2009-08-29 | |
| P1433 | published in | Cancer Letters | Q326372 |
| P1476 | title | Novel targeted therapeutics for metastatic castration-resistant prostate cancer | |
| P478 | volume | 291 |
| Q28533254 | A Rac1/Cdc42 GTPase-specific small molecule inhibitor suppresses growth of primary human prostate cancer xenografts and prolongs survival in mice |
| Q37505601 | ARP2, a novel pro-apoptotic protein expressed in epithelial prostate cancer LNCaP cells and epithelial ovary CHO transformed cells |
| Q39396713 | Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma |
| Q39549271 | Alternol exerts prostate-selective antitumor effects through modulations of the AMPK signaling pathway |
| Q36181578 | Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures |
| Q57112593 | Concise Review: Prostate Cancer Stem Cells: Current Understanding |
| Q21284745 | Emerging molecularly targeted therapies in castration refractory prostate cancer |
| Q36929648 | Emerging therapies in castrate-resistant prostate cancer |
| Q37830914 | Endothelins and their receptors in cancer: identification of therapeutic targets |
| Q33832517 | Gene expression pathways of high grade localized prostate cancer |
| Q34293602 | Generation and screening of monoclonal antibodies for immunoPET imaging of IGF1R in prostate cancer |
| Q43867243 | Immunohistochemical expression of PDGFR, VEGF-C, and proteins of the mToR pathway before and after androgen deprivation therapy in prostate carcinoma: significant decrease after treatment. |
| Q38760500 | MiRNA 34a: a therapeutic target for castration-resistant prostate cancer |
| Q35823109 | MicroRNA Library-Based Functional Screening Identified Androgen-Sensitive miR-216a as a Player in Bicalutamide Resistance in Prostate Cancer |
| Q30570945 | Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives |
| Q28482249 | Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening |
| Q38785291 | Molecular characterization of a novel androgen receptor transgene responsive to MicroRNA mediated post-transcriptional control exerted via 3'-untranslated region. |
| Q38408932 | Morphoproteomics demonstrates activation of mammalian target of rapamycin pathway in papillary thyroid carcinomas with nuclear translocation of MTOR in aggressive histological variants |
| Q26827515 | New drugs for prostate cancer |
| Q35838821 | Oncogenic activation in prostate cancer progression and metastasis: Molecular insights and future challenges |
| Q47912397 | PD-L1 in immune-escape of breast and prostate cancers: from biology to therapy |
| Q41098267 | Polyisoprenylated cysteinyl amide inhibitors induce caspase 3/7- and 8-mediated apoptosis and inhibit migration and invasion of metastatic prostate cancer cells |
| Q46537204 | Prostate cancer health disparities: An immuno-biological perspective |
| Q36160805 | Prostate-cancer-targeted N-(2-hydroxypropyl)methacrylamide copolymer/docetaxel conjugates |
| Q34490721 | Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype |
| Q37974971 | Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature |
| Q47909330 | Rapamycin promotes osteogenesis under inflammatory conditions. |
| Q30410739 | Regulation of several androgen-induced genes through the repression of the miR-99a/let-7c/miR-125b-2 miRNA cluster in prostate cancer cells |
| Q34294283 | Short hairpin RNA library-based functional screening identified ribosomal protein L31 that modulates prostate cancer cell growth via p53 pathway |
| Q51303117 | Suppression of mTOR signaling pathway promotes bone marrow mesenchymal stem cells differentiation into osteoblast in degenerative scoliosis: in vivo and in vitro. |
| Q34577158 | T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics |
| Q35063782 | The impact of IGF-1R expression on the outcomes of patients with breast cancer: a meta-analysis |
| Q85724375 | What is the role of bosentan in healing of femur fractures in a rat model? |
| Q39239023 | [99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours |
| Q37437211 | c-Src/Cav1-dependent activation of the EGFR by Dsg2 |
Search more.